Stop Doing
Business with Russia
Russia initiated aggression against Ukraine in 2014. On February 24, 2022, it started a full-scale military invasion to the Ukrainian territory. This brutal war and military crimes of Russian troops caused a humanitarian crisis in Ukraine with thousands civilians killed and millions becoming refuges. As a reaction to this act of aggression, many international companies decided to leave the Russian market, while some others continue doing business there as usual. We track such decisions of companies and urge them to stop funding the war.
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Pausing InvestmentsReducing Activities: company scaling back some business operations while continuing others
Scaling BackPause operations: company temporarily curtailing operations while keeping return options open
SuspensionClean Break: the company completely halting Russian engagements or exiting Russia
WithdrawalExit Completed: company sold its business/assets or its part of the business to a local partner and leaved the market or liquidated local entity(ies)
Exit Completed
Japan’s Takeda suspends new clinical trials in Russia and halts new investments in Russia, Supplies of drugs and clinical trials will continue. Takeda has taken further action to discontinue activities in Russia that are not essential to maintaining supply of medicines to patients and providing ongoing support to employees. This includes suspending all new investments, suspending advertising and promotion, not initiating new clinical trials and stopping enrollment of new patients in ongoing clinical trials.
Continue doing business as usual. Significantly reduced revenue in 2023 vs 2022.
Suspend sales and shipments to Russia but independent sellers remain operational. Significantly reduced revenue in 2023 vs 2022. Not officially - continues to sell its products "off the shelf". On the local website - new products. Consumers receive products with Russian descriptions and marketing materials in Russian. Product distributors ("independent partners", "distributors") actively continue to sell and promote products in VK, Telegram communities, etc. Revenue decreased in 2024 vs 2023 by more than -20%.
Received revenues in Russia in 2021-2024, there is no any official announcement. Significantly reduced revenue in 2023 vs 2022. Revenue decreased in 2024 vs 2023 by more than -20%.
Halt sales and production in Russia. Revenue decreased in 2024 vs 2023 by more than -20%.
Restrict Russian operations to medical services. Significantly reduced revenue in 2023 vs 2022.
Received revenues in Russia in 2021-2024, there is no any official announcement. Significantly reduced revenue in 2023 vs 2022. Revenue decreased in 2024 vs 2023 by more than -10%.
The US drugmaker Baxter, one of the largest suppliers of dialysis solutions, has suspended its commercial activities in Russia, according to recent statements made in the company’s explanatory note to the annual financial statements of its Russian subsidiary for 2023.
The largest U.S. marijuana company received hundreds of millions of dollars in funding from Roman Abramovich in its early years, but the Russian billionaire is long gone, Curaleaf Holdings Inc.'s chief executive said. Boris Jordan. The leaked documents show that Abramovich funded Palliatech, the company that became Curaleaf in 2018, as well as Measure 8, a cannabis-focused venture capital firm founded by Jordan. Company spokeswoman Tracy Brady said Abramovich has no ownership or influence over the company. “Massachusetts regulators have already closed their investigation into this very matter after concluding that what we have consistently argued; No undisclosed control or ownership by any foreign investor exists and Curaleaf has complied with all relevant rules and regulations.”
De Heus, a pet food company owned by one of the richest families in the Netherlands, has been sending medicine and other goods to Russian soldiers on the front in Ukraine through its Russian joint venture. In Russia, De Heus has a controlling stake in a joint venture with the Russian company MKorma. Under the name PJSC De Heus, they operate a plant in the city of Lakinsk, where they produce so-called premixes – concentrated feed for newborn piglets and chickens. The plant, acquired and modernized in 2009, claims to be the number one in Russia. De Heus is still active in Russia thanks to its “contribution to the main food chains.” De Heus Animal Nutrition has announced that it completely distances itself from recent statements and actions of its Russian joint venture MKorma. The Dutch animal feed company emphasizes that it no longer has any say in the company's activities in Russia. De Heus is pushing for a permanent departure from the country.
We recently made the difficult decision to pause ECFMG Certification services requested by Russian citizens residing in Russia, We look forward to a time when we can resume our ECFMG Certification services to Russian applicants.
All non-essential business operations in the country have been suspended, Any profits made from the sale of medicines will be donated to the humanitarian efforts for Ukraine
Online store selling vitamins iHerb has suspended delivery to Russia.
Suspended all operations, most supplies, and all advertising
No public statement found. (Distribution office in Moscow)
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm. 11.2023: The entry about the founder of STADA ARTSNAIMITTEL was removed from the Unified State Register of Legal Entities. AGNIDDA LINKS S.A.R.L. becomes the new founder of the organization (probably internal deal). One of the largest German investors in the pharmaceutical industry of the Russian Federation, the company Stada, is moving its plants into a separate company and preparing them for sale. Vladimir Putin has transferred the management of one of Russia's largest pharmaceutical manufacturers, Nizhpharm, under temporary control. The decree applies to 100% of the shares owned by Luxembourg-based Nidda Lynx S.A.R.L., which is part of the German Stada group. The new temporary manager of the assets is the Russian company Farmirus. It was founded in 2020 and specializes in the supply of medicines. In 2022, the company operated at a loss with revenue of about 92 million rubles ($1 million).
Acino's parent company, headquartered in Zurich, Switzerland, sold an asset in the Russian Federation in 2023 and no longer does business in that country. But Acino doesn't appear to have totally left Russia, they seem to have transferred the shares to a related companies in the UAE. The parent company of ACINO is ADQ based in UAE. Acino in Switzerland has made no official announcement that they left Russia.
The company continues to operate in Russia. Revenue significantly (by more than -70%) decreased in 2024 vs 2023.
Continued business with Russia and exports. There were no official press releases to leave market. 3Shape still keep support and software upgrades for TRIOS scanners in russia. So russians are able to receive higher quality of dental patients care. 3Shape has ceased selling products in several countries based on increased risks of chemical weapons, cyber-attacks, human rights violations, and terrorism, including Russia.
All Agilent offices have now been closed in Russia, and Agilent business operations in the country were halted as of May 23.
Discontinue all sales into Russia, direct and indirect
BMS is handing over its Russian commercial operations to its distribution partner Swixx Healthcare, previously known as Amicus, a Bristol spokesperson said over email
Received revenues in Russia in 2021-2023, there is no any official announcement. Revenue significantly (by more than -70%) decreased in 2024 vs 2023, to zero.
Suspend new investments and clinical trials. The American pharmaceutical company Eli Lilly has decided to leave Russia and transfer its business to its partner in Central and Eastern Europe — the Swiss-registered distributor Swixx Biopharma. The company will hand over business in the country to Swixx BioPharma. Through it, Eli Lilly will continue to supply drugs to Russia. The American Eli Lilly has banned the supply of Humalog insulin to Russia. Revenue significantly (by -99%) decreased in 2024 vs 2023.
Received revenues in Russia in 2021-2023, there is no any official announcement. Significantly reduced revenue in 2023 vs 2022. Revenue significantly (by -92%) decreased in 2024 vs 2023.
The Trump administration has blocked access to multiple data repositories maintained by the National Institutes of Health (NIH) for researchers in several countries, including a cancer statistics database used heavily by scientists in China. The ban is effective April 4, 2025 and applies to institutions in China, Hong Kong, Macau, Russia, Iran, North Korea, Cuba and Venezuela.
Ovoca Bio PLC agrees to dispose of some of its Russian assets to Desirix LLC for EUR1.1 million. Upon completion, all operational activities of Ovoca in Russia will cease and its Russian subsidiary, IVIX LLC, will be transferred to an inactive, non-operating status.
Exits Russia till the end of June 2022. All Watsons stores in Russia are closed as early as the summer of 2022 (the closing process has been ongoing since the first days of Russia's full-scale invasion of Ukraine); all employees are dismissed, except for two for reporting, other administrative work, since closing a legal entity takes more time than a store; further liquidation of the legal entity in Russia is planned; the page https://www.instagram.com/watsonsrussia/ is closed and does not work; the Russian website also no longer exists. That is, in fact, commercial activity will be suspended in the summer of 2022 with the subsequent liquidation of legal entities.